Top Markets
#1 ONFA ONFA +225.03%
#2 Resolv wstUSR Resolv wstUSR +198.11%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 NKN NKN +36.62%
#6 DeAgentAI DeAgentAI +32.88%
#7 StakeStone StakeStone +27.06%
#8 BLOCKv BLOCKv +26.09%
#9 KONET KONET +22.11%
#10 OpenVPP OpenVPP +21.99%
Coin of the day
ONFA ONFA
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rang in Aktien #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Aktienkurs
$0.5275
Marktkapitalisierung
$1.25M
Veränderung (1 Tag)
-3.56%
Veränderung (1 Jahr)
-83.77%
Land
US
Handel Ensysce Biosciences, Inc. (ENSC)

Kategorie

Healthcare
Operative Marge für Ensysce Biosciences, Inc. (ENSC)
Operative Marge zum March 2026 TTM: -245.89%
Laut den neuesten Finanzberichten und dem Aktienkurs von Ensysce Biosciences, Inc. beträgt die aktuelle operative Marge (TTM) -245.89%. Am Ende des Jahres 2023 lag die operative Marge bei -480.41%.
Historie der operativen Marge von Ensysce Biosciences, Inc. von 2017 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -245.89% 90.36%
2024 -129.17% -73.11%
2023 -480.41% -49.96%
2022 -960.05% 70.61%
2021 -562.73% 1,271.51%
2020 -41.03% -78.26%
2019 -188.72% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.17%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.14%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.10%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.10%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.10%
AU
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.